CETP inhibitors
Drugs that block cholesteryl ester transfer protein, studied for lowering LDL cholesterol.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 6, 5, 4, 1, 3.
All papers from the last 12 months
55 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Structure-guided design of N-alkylated benzazepine derivatives as potential CETP inhibitorsBioorg Chem2026 Oct 15PMID 42767172
- Emerging therapeutic strategies to target APOE4 in Alzheimer's diseaseFEBS J2026 Oct 5PMID 42831701Review
- HDL-associated proteins affecting CVD and systemic inflammationCurr Opin Lipidol2026 Oct 1PMID 42578565Review
- Cholesteryl Ester Transfer Protein Inhibition and Risk of Age-Related Macular DegenerationOphthalmology2026 Sep 29PMID 42810526
- Beyond Traditional Lipid Lowering: Obicetrapib and the Renaissance of Cholesteryl Ester Transfer Protein InhibitionEur Cardiol2026PMID 42866070Review
- Progress on cholesteryl ester transfer protein-related genes and CETP inhibitor therapyYi Chuan2026 SepPMID 42751822Review
- Reducing CETP activity prevents memory decline in an Alzheimer's disease mouse modelEMBO Mol Med2026 SepPMID 42547584
- Comparative Biomarker Efficacy of CETP Inhibitors: A Network Meta-AnalysisEur Heart J Cardiovasc Pharmacother2026 Aug 28PMID 42663147
- Synthesis and Computational Analysis of Para-fluorinated Phenoxymethyl Benzenesulfonamides as Potential CETP InhibitorsCurr Comput Aided Drug Des2026 Aug 27PMID 42695295
- Obicetrapib-ezetimibe combination therapy: a novel oral strategy for enhanced lipid loweringCardiovasc Res2026 Aug 14PMID 42598909
More cardiology trends
All specialties →Factor XI inhibitors
A newer class of anticoagulants that target factor XI or XIa.
Key point: Adding an FXIa inhibitor to standard antiplatelet therapy after acute noncardioembolic ischemic stroke or TIA reduces stroke recurrence without evidence of increased bleeding risk.
Colchicine in cardiovascular disease
Colchicine as an anti-inflammatory therapy in coronary and cardiovascular disease.
Key point: Low-dose colchicine has demonstrated modest reductions in cardiovascular events, although results across trials have been inconsistent.
Renal denervation
A catheter procedure targeting renal nerves to lower blood pressure.
Intravascular lithotripsy
Shockwaves delivered through a balloon catheter to crack calcium in arteries.
New antihypertensive drugs
New blood pressure drugs, including aldosterone synthase inhibitors and zilebesiran.
Key point: Aldosterone-targeted therapies, including aldosterone-synthase inhibitors and spironolactone, provide clinically meaningful systolic blood pressure reductions in resistant hypertension without increasing serious adverse events.
Vutrisiran
Studies of vutrisiran, an RNA interference therapy for transthyretin amyloidosis.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
obicetrapib[tiab] OR "CETP inhibitor"[tiab] OR "CETP inhibition"[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.